Subgroup analyses on gastric cancer (RR 0.73, 95% CI: 0.13–4.02, I2: 0%) and pancreatic cancer (RR 0.58, 95% CI: 0.18–1.85, I2: 0%) showed no significant association between G-CSF use and AEs. Here, CSF3 is linked to gastric cancer.